#30: Biovest Reports Blinded Results for Phase 3 Study Evaluating Anti-Cancer Vaccine, BiovaxID(R), which Shows 100% Difference in Disease-Free Survival at 36 Months in the Comparative Arms
Final Unblinded Results Are Expected to Confirm Efficacy Of BiovaxID
for the Treatment of Non-Hodgkin’s Lymphoma
Biovest International, Inc. (OTCBB:BVTI), a...
Company Affirms Plans to Unblind and Report Fast Track Pivotal
Phase 3 Results for SinuNase™ in March
Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI stock message board) today...
Accentia Biopharmaceuticals Reports Fiscal
2007 Year-End Results; Pivotal Phase III Results Pending for
SinuNase(TM) and BiovaxID(TM)
Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI)...
Biovest International, Inc. (OTCBB:BVTI), a majority owned subsidiary of
Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), will present at the
Rodman & Renshaw Acumen BioFinTM...
TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals (NASDAQ:ABPI) -- Television stations across the country recently interviewed Dr. David Sherris, co-inventor of SinuNase™...
#25: ABPI News Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology
TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI), presented three posters at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology...
TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) has acquired the exclusive worldwide rights for Revimmune™, a patent-pending pharmaceutical...
TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) entered into a definitive agreement for a convertible debenture financing with several institutional...
TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) notes that its
consolidated financial statements for the fiscal year ended September
30, 2006, including...
TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI; “Accentia”;
“Company”), has
released the results of its operations for the...
TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals (NASDAQ: ABPI)
has entered into mutual confidentiality agreements with several
pharmaceutical companies that have established...
TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), presented three posters
at the American College of Allergy, Asthma and Immunology from November 9th ...
#18: ABPI News Report Shows Use of a SinuNase Formulation is Associated With a Significant, 74% Reduction in Reoperations for Chronic Sinusitis Patients Who Are Refractory to Sinus Surgery
TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals (NASDAQ: ABPI)
has announced that in a study of chronic sinusitis (CS) patients
refractory to sinus surgery, treated with...
TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals (NASDAQ: ABPI)
will begin enrolling patients for its Phase 3 study of SinuNase™
in November and will include patients...
TAMPA, Fla.--(BUSINESS WIRE)--A majority-owned subsidiary of Accentia Biopharmaceuticals Inc. (NASDAQ:
ABPI), Biovest International, Inc. (OTCBB: BVTI), announced that it has
launched...
